Wang Jian-Cheng, Tian Jin-Hui, Ge Long, Gan Yu-Hong, Yang Ke-Hu
Evidence-based Medicine Center of Lanzhou University, Lanzhou, Gansu, China E-mail :
Asian Pac J Cancer Prev. 2014;15(12):4795-800. doi: 10.7314/apjcp.2014.15.12.4795.
Few studies have directly compared clinical efficacy and safety among Chinese herb injections (CHIs) for gastric cancer (GC). The present study aimed to compare CHIs combined with FOLFOX regimens for GC to show which provides the best CHIs results.
9 electronic databases and 6 gray literature databases were comprehensive searched in April 20, 2013. According to inclusion and exclusion criteria, two reviewers independently selected and assessed the included trials. The risk of bias tool described in the Cochrane Handbook version 5.1.0 and CONSORT statement were used to assess the quality of the trials. All calculations and graphs were performed and produced using ADDIS 1.16.5 software.
A total of 541 records were searched and 38 RCTs met the inclusion criteria (2,761 participants), involving 10 CHIs. The results of network meta-analysis showed that compared with FOLFOX alone, combinations with Kanglaite, Astragalus polysaccharides, Cinobufacini, or Yadanziyouru injections could furthest strengthen ORR, improve the quality of life, reduce nausea and vomiting, and reduce the incidence of leukopenia (III-IV).
Kanglaite injection, Astragalus polysaccharides injection, Yadanziyouru injection were superior to other CHIs in clinical efficacy and safety for GC. The conclusions now need to be confirmed by large sample size direct head-to-head studies.
很少有研究直接比较中药注射剂(CHIs)治疗胃癌(GC)的临床疗效和安全性。本研究旨在比较CHIs联合FOLFOX方案治疗GC,以确定哪种CHIs效果最佳。
2013年4月20日全面检索了9个电子数据库和6个灰色文献数据库。根据纳入和排除标准,两名评价者独立选择并评估纳入的试验。采用Cochrane手册5.1.0版中描述的偏倚风险工具和CONSORT声明来评估试验质量。所有计算和图表均使用ADDIS 1.16.5软件进行和生成。
共检索到541条记录,38项随机对照试验符合纳入标准(2761名参与者),涉及10种CHIs。网络荟萃分析结果显示,与单纯FOLFOX相比,联合康莱特、黄芪多糖、华蟾素或鸦胆子油乳注射液可最大程度增强客观缓解率(ORR),改善生活质量,减少恶心和呕吐,并降低白细胞减少症(III-IV级)的发生率。
康莱特注射液、黄芪多糖注射液、鸦胆子油乳注射液在GC的临床疗效和安全性方面优于其他CHIs。目前这些结论需要通过大样本量的直接头对头研究来证实。